IGM Biosciences Stock: Bad News With No Turnaround In Sight
IGM Biosciences has halted all oncology programs and faces a significant pipeline upheaval. Read why I maintain my Sell ...
BioSpace6h
IGM Biosciences Lays Off 73% of Staff, Shrinks Pipeline
Staff cuts could leave IGM Biosciences with fewer than 55 employees. The company is also halting development of two ...
FierceBiotech3h
IGM, Y-mAbs, Passage Bio and more telegraph staff cuts amid restructuring spree
Just two weeks into 2025, January is proving why it’s earned a reputation as the worst month for layoffs. | Just two weeks ...
IGM Bio plunges as Wall Street downgrades on portfolio shakeup
IGM Biosciences (NASDAQ:IGMS) lost nearly two-thirds of its value on Friday after the company abandoned two antibody-based ...
IGM Biosciences price target lowered to $2 from $12 at Truist
Truist analyst Asthika Goonewardene lowered the firm’s price target on IGM Biosciences (IGMS) to $2 from $12 and keeps a Hold rating on the ...
The Armenian Reporter4h
Jefferies Financial Group Reiterates “Hold” Rating for IGM Biosciences (NASDAQ:IGMS)
IGM Biosciences (NASDAQ:IGMS – Get Free Report)‘s stock had its “hold” rating reiterated by Jefferies Financial Group in a ...
IGM to slash 73% of workforce, halt two drug programs
IGM Biosciences (IGMS) is slashing its workforce by 73% and discontinuing development of two of its lead drug candidates in ...
Jefferies downgrades IGM Biosciences (IGMS) to a Hold
IGM Biosciences (IGMS – Research Report) received a Hold rating and a $2.00 price target from Jefferies analyst Roger Song today. The company’s ...
IMG Biosciences enacts massive lay-offs after Phase I trial failure
Following the negative Phase I trial outcome for its autoimmune disease treatment, the company is cutting 73% of jobs.